Vistagen Therapeutics (VTGN) Enterprise Value (2016 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Enterprise Value for 14 consecutive years, with -$61.8 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 30.25% to -$61.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$61.8 million through Dec 2025, up 30.25% year-over-year, with the annual reading at -$80.5 million for FY2025, 32.46% up from the prior year.
- Enterprise Value hit -$61.8 million in Q4 2025 for Vistagen Therapeutics, up from -$77.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$9.6 million in Q2 2023 to a low of -$126.6 million in Q4 2023.
- Historically, Enterprise Value has averaged -$72.3 million across 5 years, with a median of -$78.8 million in 2025.
- Biggest five-year swings in Enterprise Value: crashed 7508.91% in 2021 and later skyrocketed 81.53% in 2023.
- Year by year, Enterprise Value stood at -$83.7 million in 2021, then surged by 70.09% to -$25.0 million in 2022, then crashed by 405.48% to -$126.6 million in 2023, then soared by 30.02% to -$88.6 million in 2024, then surged by 30.25% to -$61.8 million in 2025.
- Business Quant data shows Enterprise Value for VTGN at -$61.8 million in Q4 2025, -$77.2 million in Q3 2025, and -$63.2 million in Q2 2025.